Narcolepsy

Findings indicated that the robust wake-promoting efficacy of solriamfetol demonstrated in clinical trials resulted in improved real-world functional performance in participants with narcolepsy.

Data showed improvement in excessive daytime sleepiness and cataplexy frequency for children with narcolepsy on pitolisant.

For Valentine’s Day, the senior behavioral scientist at the RAND Corporation talked about the significance of sleep health and romantic relationships [WATCH TIME: 5 minutes]

A web-based survey of Korean neurologists interested in narcolepsy presented their concerns with using the multiple sleep latency test, noting that it may lead to ambiguous results due to accompanying sleep disorders like sleep apnea.

Glymphatic function demonstrated no significant difference in patients with type 1 and type 2 narcolepsy in comparison with healthy controls.

A questionnaire showed that adolescents with narcolepsy and parents prefer to receive details on narcolepsy at the time of diagnosis from a healthcare provider.

When asked which efficacious diagnostic or treatment options they hope to see in the future, a majority of physicians, especially specialists, expressed a desire to see more useful biomarkers, followed by more effective diagnostic tests overall.

A survey based on young adult college students indicated that symptoms of insomnia might buffer the association with the acute physiological effects of alcohol, in part because it may heighten the sensitivity to alcohol.

Richard Bogan, MD, FCCP, FAASM, associate clinical professor, University of South Carolina School of Medicine, provided commentary on multifunctional capabilities of Xywav and how the medication has improved care for narcolepsy and idiopathic hypersomnia.